Skip to main content

Table 1 Demographic data (mean ± SEM,n= 42, except when marked otherwise)

From: Safety and economic considerations of argatroban use in critically ill patients: a retrospective analysis

Age (years) 61 ± 2.4
Body weight (kg) 84.4 ± 3.2
Body Mass Index kg/m2 29.2 ± 1.2
Length of ICU-Stay (days) 15 ± 2.9
history of HIT 6.0 ± 1.2, n = 23
no history of HIT 25.8 ± 5.0, n = 19
SAPS <30 11 ± 3.0, n = 16
SAPS >30 18 ± 4.2, n = 26
SAPS score on ICU admission 34 ± 2.2
Sepsis 14 (33%)
Renal replacement therapy 17 (40.5%)
Respiratory failure 31 (73.8%)
Veno-arterial ECMO 1 (2.4%)
Death* 6 (14.2%)
  1. *Death was unrelated to bleeding, thromboembolic complication or argatroban.